Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at Roth Capital issued their Q4 2025 earnings per share estimates for shares of Zevra Therapeutics in a report released on Tuesday, November 12th. Roth Capital analyst J. Aschoff expects that the company will earn $0.04 per share for the quarter. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.63) per share.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. During the same quarter in the prior year, the firm earned ($0.15) EPS.
A number of other equities research analysts have also commented on the company. Roth Mkm increased their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Monday, September 30th. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 price objective for the company. Finally, Maxim Group boosted their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $21.00.
Read Our Latest Analysis on Zevra Therapeutics
Zevra Therapeutics Stock Up 4.3 %
Shares of Zevra Therapeutics stock traded up $0.37 on Thursday, hitting $9.03. The company had a trading volume of 941,388 shares, compared to its average volume of 544,623. Zevra Therapeutics has a 1 year low of $4.18 and a 1 year high of $9.21. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a 50 day moving average of $7.97 and a 200-day moving average of $6.44. The stock has a market capitalization of $475.16 million, a price-to-earnings ratio of -4.57 and a beta of 1.93.
Institutional Investors Weigh In On Zevra Therapeutics
Large investors have recently modified their holdings of the stock. FMR LLC grew its holdings in Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company's stock valued at $16,054,000 after purchasing an additional 2,312,384 shares during the period. Stonepine Capital Management LLC purchased a new position in shares of Zevra Therapeutics during the 3rd quarter valued at $4,858,000. Vestal Point Capital LP purchased a new position in shares of Zevra Therapeutics during the 3rd quarter valued at $3,644,000. Propel Bio Management LLC bought a new position in shares of Zevra Therapeutics during the 3rd quarter worth $1,248,000. Finally, Simplify Asset Management Inc. purchased a new stake in Zevra Therapeutics in the 3rd quarter worth about $833,000. Hedge funds and other institutional investors own 35.03% of the company's stock.
About Zevra Therapeutics
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
See Also
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
